Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + tositumomab
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Bortezomib + tositumomab is a combination of two anticancer agents with distinct mechanisms of action. Bortezomib is a small molecule proteasome inhibitor that blocks the 26S proteasome, leading to disruption of protein degradation and induction of apoptosis in cancer cells. It is primarily used for multiple myeloma and mantle cell lymphoma. Tositumomab is a murine monoclonal antibody targeting the CD20 antigen on B-cells, often conjugated with radioactive iodine (Iodine 131) to deliver targeted radiation therapy; it was developed for the treatment of B-cell non-Hodgkin's lymphoma. The combination would theoretically provide both direct cytotoxicity via proteasome inhibition and targeted immunotherapy/radioimmunotherapy against malignant B-cells[1][2][3][6].
- Brand names
- Boruzu
- Other names
- Iodine I 131 tositumomab
02
Targets
CD20 (B-lymphocyte antigen CD20)PSMB1 (26S Proteasome (β1-Subunit))PSMB9 (Immunoproteasome subunit beta type-1i)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on bortezomib + tositumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + tositumomab.